Table 3.
Changes Between Baseline and Week 96 in Human Immunodeficiency Virus Disease, Metabolic, and Mitochondrial Indices in Patients Receiving Efavirenz Versus Atazanavir-Ritonavir (n = 39)
| Index | EFV | P (Within EFV) | ATV/r | P (Within ATV/r) | P (Between Groups) |
|---|---|---|---|---|---|
| CD4 count, cells/μL | 144 (108–292) | <.001 | 250 (210–352) | <.001 | .22 |
| Log10 HIV-1 RNA, copies/mL | −3.8 (−4.1 to −3.1) | <.001 | −3.7 (−4.3 to −3.1) | <.001 | .85 |
| BMI, kg/m2 | 1.1 (−0.3 to 2.2) | .25 | 1.6 (0.3–4.4) | <.001 | .24 |
| Limb fat, g | 812 (−349 to 1503) | .14 | 1807 (391–2982) | <.001 | .053 |
| Visceral fat, cm2 | 11.5 (−17.6 to 30.9) | .48 | 18.9 (−0.2 to 33.6) | .01 | .40 |
| Fat mtDNA, copies/cell | −434 (−1000 to 90) | .006 | −351 (−576 to −49) | .001 | .45 |
| Complex I activity, OD × 103/µg | −0.85 (−20.2 to 8.8) | .15 | −2.4 (−15.9 to 2.9) | .09 | .99 |
| Complex IV activity, OD × 103/µg | −10.0 (−13.8 to −1.3) | .005 | −3.7 (−7.3 to 0.2) | .01 | .39 |
The nucleoside reverse-transcriptase inhibitors were combined in this comparison. Values represent median change (interquartile range).
Abbreviations: ATV/r, atazanavir-ritonavir; BMI, body mass index; complex I, nicotinamide adenine dinucleotide (reduced) dehydrogenase; complex IV, cytochrome c oxidase; EFV, efavirenz; mtDNA, mitochondrial DNA levels; HIV-1, human immunodeficiency virus type 1; OD, optical density.